What Is Low Dose Naltrexone? Uses, Evidence, Safety, and Compounding

Low Dose Naltrexone, commonly called LDN, is receiving growing attention from people researching fibromyalgia, persistent pain, and personalized functional medicine.

The interest is real. So is the uncertainty.

LDN is not a supplement, peptide, opioid, or FDA approved treatment for chronic pain. It is a lower dose, off-label use of the prescription medication naltrexone. Some clinical studies suggest that selected patients may experience symptom improvement, while other trials and reviews have not found a meaningful advantage over placebo.

The most responsible way to understand LDN is to answer four separate questions:

1. What is the medicine?

2. What does the evidence show?

3. What are the risks, especially with opioids?

4. Why might a prescriber request a compounded preparation?

What Is Low Dose Naltrexone?

Naltrexone is an opioid receptor antagonist. It binds to opioid receptors and blocks the effects of opioid drugs.

FDA approved oral naltrexone tablets are available in a 50 mg strength and are indicated for alcohol dependence and for blocking the effects of externally administered opioids as part of an appropriate treatment plan. Review the current naltrexone prescribing information through DailyMed.

“Low Dose Naltrexone” is a clinical term rather than an FDA defined product. A 2026 evidence review described off-label LDN use at approximately 0.5 mg to 6 mg, with 4.5 mg used most often in the studies it evaluated. The appropriate prescription, if any, depends on the patient and prescriber. Read the 2026 evidence review.

Using naltrexone at a lower dose for fibromyalgia, chronic pain, or other commonly discussed conditions is off label. Off-label prescribing is a recognized part of medical practice, but it means the FDA has not approved the drug as safe and effective for that particular use.

Is LDN the Same as Standard Naltrexone?

LDN uses the same active ingredient as standard oral naltrexone, but the strength, intended use, evidence, and preparation may differ.

Important: Lower dose does not mean risk free. The opioid interaction remains central to safe prescribing.

What Is LDN Used For?

Clinicians have prescribed LDN off label for selected patients with conditions that may involve persistent pain or other complex symptoms.

Areas discussed in the clinical literature include:

1. Fibromyalgia

2. Other chronic pain conditions

3. Multiple sclerosis related symptoms or quality of life

4. Crohn’s disease

5. Selected dermatologic conditions

6. Postinfectious symptoms, including Long COVID

This list describes areas of research and off-label clinical interest. It is not a list of FDA approved indications, and it does not establish that LDN is effective for every person or condition.

LDN should not replace an established treatment solely because it is popular online or described as “functional medicine.”

What Does the Evidence Show?

The short answer

The evidence is promising in some studies, negative in others, and not strong enough to support broad claims.

A 2024 meta-analysis pooled four randomized controlled trials involving 222 people with fibromyalgia. It reported a greater reduction in pain scores with LDN than with placebo. It did not find significant differences in several other measures, including the revised Fibromyalgia Impact Questionnaire. Vivid dreams and nausea occurred more often with LDN. Review the 2024 meta-analysis.

Other evidence has been less favorable. A 2024 systematic review of randomized trials across diverse chronic pain conditions concluded that results were inconsistent and did not support LDN as an effective general treatment for chronic pain. The authors emphasized small samples and varying methods. Review the chronic pain systematic review.

The broadest current review, published in 2026, evaluated 105 studies, including 15 randomized controlled trials. It found that early positive results from uncontrolled studies were rarely replicated in placebo controlled trials. The authors concluded that available evidence does not support routine clinical use, while noting that LDN may have a pragmatic role in selected treatment resistant cases when its experimental status and uncertain efficacy are clearly explained. Review the 2026 evidence assessment.

Evidence by condition

Condition or use	What the evidence suggests	Confidence
Fibromyalgia	Some small trials and pooled analyses suggest pain improvement, while other trials and outcomes are negative	Limited and mixed
Chronic pain broadly	Results vary by pain condition, and a 2024 review did not support general effectiveness	Limited and inconsistent
Crohn’s disease	Small studies suggest possible benefit, but a Cochrane review found insufficient evidence for firm conclusions	Low certainty
Multiple sclerosis	Small studies have examined tolerability and quality of life, but LDN is not an established disease modifying treatment	Limited
Long COVID and postviral symptoms	Early observational and feasibility research exists, but efficacy remains uncertain	Preliminary
Autoimmune conditions broadly	Online interest exceeds the quality and quantity of condition specific evidence	Insufficient for broad claims

 

For Crohn’s disease, a Cochrane review rated the available evidence as low quality because the studies were small and estimates were imprecise. Review the Cochrane analysis through PubMed.

How Might LDN Work?

Naltrexone’s established action is opioid receptor antagonism.

Researchers have proposed additional low dose effects involving pain signaling, glial cells, immune pathways, and endogenous opioid activity. These proposed mechanisms help explain scientific interest in LDN, but they do not prove that the medication improves symptoms in an individual patient.

Mechanism should never be confused with outcome.

A medication can have a biologically plausible mechanism and still fail to produce a meaningful benefit in a well controlled clinical trial.

Is Low Dose Naltrexone FDA Approved?

Naltrexone is FDA approved for specific substance use related indications. LDN use for chronic pain, fibromyalgia, autoimmune symptoms, and similar conditions is off label.

When a pharmacy prepares a patient specific LDN strength, the finished compounded medication is also not FDA approved. The FDA does not verify the safety, effectiveness, or quality of a compounded drug before it is marketed. The agency also recognizes that compounding can meet an important patient need when an FDA approved product is not medically appropriate for that patient. Read the FDA’s compounding questions and answers.

These statements can both be true:

1. Compounding may help meet a legitimate patient specific need.

2. A compounded preparation is not FDA approved.

Why Is LDN Often Compounded?

Commercial oral naltrexone tablets are commonly supplied at 50 mg. A prescriber who chooses a much lower patient specific strength may request a compounded capsule or other dosage form.

A compounding pharmacy may help by:

1. Preparing the strength and dosage form specified in a valid prescription

2. Reviewing the prescription for clarity and potential medication conflicts

3. Counseling the patient on the prescribed preparation

4. Coordinating questions with the prescriber

5. Supporting refill continuity and appropriate storage

Compounding does not prove that LDN will work, and it does not convert an off-label use into an FDA approved one. Its role is to fulfill a patient specific prescription when compounding is appropriate.

What Are the Most Important LDN Safety Concerns?

Opioid exposure

The most important preventable medication conflict involves opioids.

Current naltrexone labeling lists the medication as contraindicated in patients receiving opioid analgesics, patients currently dependent on opioids, and patients in acute opioid withdrawal. Starting naltrexone in a person who is physiologically dependent on an opioid can precipitate sudden withdrawal, which may be severe. Review the contraindications and warnings in DailyMed.

Before considering LDN, tell the prescriber and pharmacist about:

1. Hydrocodone, oxycodone, codeine, morphine, or fentanyl

2. Tramadol

3. Methadone

4. Buprenorphine

5. Opioid containing cough or diarrhea medicines

6. Current or recent nonprescribed opioid exposure

7. Planned surgery, dental work, or other procedures that may require pain control

Do not stop an opioid, estimate an opioid free interval, or start LDN without direct guidance from the treating clinician.

Side effects

Effects reported in LDN studies and standard naltrexone information include:

1. Vivid dreams

2. Sleep changes or insomnia

3. Nausea

4. Headache

5. Dizziness

6. Fatigue

7. Abdominal discomfort

Patients should contact the prescribing team about persistent, severe, unexpected, or worsening symptoms. Worsening symptoms are not proof of a “detox” or evidence that LDN is working.

Naltrexone labeling also includes liver related warnings. Patients should discuss liver disease, abnormal liver tests, heavy alcohol use, pregnancy, breastfeeding, mental health history, and all medications and supplements with the clinical team.

How Long Does LDN Take to Work?

There is no universal timeline that applies to every patient or condition.

Published studies use different doses, treatment durations, and outcome measures. Rather than relying on a social media timeline, patients and clinicians should define the symptom being targeted and decide how progress will be measured.

Useful measures may include:

1. Average daily pain

2. Sleep interruption

3. Ability to complete normal activities

4. Frequency and severity of symptom flares

5. Fatigue and usable energy

6. Side effects and medication changes

Read the Scripx guide, How Long Does LDN Take to Work?, for a structured progress tracking framework. [Insert internal article link]

Who Should Consider Discussing LDN With a Clinician?

LDN may be worth discussing when:

1. A specific symptom or treatment goal has been identified

2. The condition specific evidence has been reviewed honestly

3. Current and recent opioid exposure has been ruled out or appropriately managed

4. Established treatment options have been considered

5. The patient and clinician agree on monitoring and reassessment

A consultation should not begin with “LDN works for everything.” It should begin with “What problem are we trying to solve, and how will we know whether this is helping?”

Questions to Ask Before Starting LDN

1. Why is LDN being considered for my specific condition?

2. What evidence supports this use?

3. Is this use FDA approved or off label?

4. Could any of my medications contain an opioid?

5. What should I do if I need surgery or emergency pain treatment?

6. Which side effects should I report?

7. How will we measure improvement?

8. When will treatment be reassessed?

9. Why is a compounded preparation being recommended?

10. Who should I contact with medication questions?

The Bottom Line

Low Dose Naltrexone is a lower dose, off-label use of naltrexone that has been studied across several chronic conditions.

Some research is encouraging, particularly in selected fibromyalgia analyses. Other trials and broader reviews have not shown consistent benefit. The most current evidence does not support describing LDN as a proven or routine treatment for chronic pain, autoimmune disease, or other broad categories.

That does not make LDN irrelevant. It makes individualized evaluation, informed consent, medication screening, measurable goals, and honest follow up essential.

Explore LDN With Scripx Pharmacy

Scripx Pharmacy provides patient specific compounding and pharmacist supported medication education for eligible patients with valid prescriptions.

A licensed clinician should review your symptoms, medical history, current medications, recent opioid exposure, and treatment goals before deciding whether LDN is appropriate.

Start an LDN evaluation: START HERE

Completing an evaluation does not guarantee eligibility, treatment, or a prescription. Telehealth evaluation and pharmacy service availability vary by state.

Already have a prescription? Contact Scripx Pharmacy to discuss prescription submission, patient specific compounding, medication questions, and available delivery options.

Scripx Pharmacy
601 W. FM 544, Suite 102
Murphy, Texas 75094
Phone: 469-596-0341
Fax: 469-596-0412

Scripx currently serves eligible patients in Texas, Florida, Michigan, Colorado, and Hawaii, subject to prescription, clinical, and pharmacy requirements.

This article is provided for general education and does not replace individualized medical advice. The LDN uses discussed are off label. Compounded medications are not FDA approved.

Frequently Asked Questions

What is Low Dose Naltrexone?

Low Dose Naltrexone is an off-label use of naltrexone at amounts below the standard 50 mg oral tablet. It has been studied for fibromyalgia, chronic pain, and other conditions, but evidence varies by condition.

Is LDN an opioid?

No. Naltrexone is an opioid receptor antagonist. It blocks opioid receptors and can interfere with opioid pain medications.

Is LDN FDA approved for fibromyalgia or chronic pain?

No. Naltrexone is FDA approved for alcohol dependence and opioid blockade, but the commonly discussed LDN uses for fibromyalgia and chronic pain are off label.

Is compounded LDN FDA approved?

No. A patient specific compounded LDN preparation is not FDA approved.

Does LDN work for autoimmune disease?

LDN has been discussed and studied in several immune related conditions, but evidence is not strong enough to support a broad claim that it treats autoimmune disease. Evidence and treatment decisions should be evaluated condition by condition.

Can I take LDN with an opioid?

Naltrexone can block opioid pain relief and may precipitate severe withdrawal in an opioid dependent person. Do not combine these medications or manage a transition without direct medical supervision.

What are common LDN side effects?

Reported effects include vivid dreams, sleep changes, nausea, headache, dizziness, fatigue, and abdominal discomfort. Persistent, severe, or worsening symptoms should be reviewed by the prescribing team.

Why is LDN compounded?

A prescriber may request a compounded preparation when the patient specific strength or dosage form is not commercially available or appropriate. Compounding does not guarantee effectiveness, and the finished preparation is not FDA approved.

How long does LDN take to work?

There is no universal timeline. Studies use different doses, durations, and endpoints. Patients should establish measurable goals and a reassessment plan with their clinician.

Where is Scripx Pharmacy licensed to provide service?

Scripx currently serves eligible patients in Texas, Florida, Michigan, Colorado, and Hawaii, subject to prescription, clinical, and pharmacy requirements. Availability should be confirmed before beginning an evaluation.